Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate outcomes of intravitreal injection of bevacizumab for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhages (VH or RH).

Methods

This is a prospective interventional case-series. Fourteen eyes of eight premature infants with severe ROP associated with vitreous or retinal hemorrhage were consecutively included. In eight eyes, VH and/or RH precluding complete laser ablation developed at the time of laser treatment. In six eyes, VH developed early after laser ablation. All participants underwent intravitreal injection of 0.625 mg (0.025 ml) bevacizumab immediately after diagnosis of VH or RH. Follow-up examinations were performed at days 1, 3, 7, and 14, and 1, 2 and 3 months after injection. Main outcome measure was the absence of unfavorable structural outcomes.

Results

Mean gestational age was 27.6 weeks (range, 26–29 weeks) and mean birth weight was 1047 g (range, 780–1500 g). Mean gestational age at the time of injection was 35.4 weeks (range, 32–38 weeks). In all eyes, plus disease disappeared completely within 2 weeks and VH and/or RH was absorbed at last follow-up. None of the eyes developed unfavorable structural outcomes. No eyes needed additional injection or laser treatment. No major systemic or ocular complications were observed.

Conclusion

In this small series of patients, intravitreal injection of bevacizumab was effective for treatment of severe retinopathy of prematurity associated with vitreous or retinal hemorrhage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity. Results of The Early Treatment for Retinopathy of Prematurity Randomized Trial. Arch Ophthalmol 121:1684–1696

    Article  CAS  PubMed  Google Scholar 

  2. Azuma N, Ishikawa K, Hama Y, Hiraoka M, Suzuki Y, Nishina S (2006) Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol 142:636–643

    Article  PubMed  Google Scholar 

  3. Micelli Ferrari T, Furino C, Lorusso VV, Dammacco R, Sborgia G, Sborgia L, Besozzi G (2007) Three-port lens-sparing vitrectomy for aggressive posterior retinopathy of prematurity: early surgery before tractional retinal detachment appearance. Eur J Ophthalmol 17:785–789

    CAS  PubMed  Google Scholar 

  4. Hutcheson KA, Nquyen ATQ, Reslan MW, Ellish NJ, Steidl SM (2003) Vitreous hemorrhage in patients with high-risk retinopathy of prematurity. Am J Ophthalmol 136:258–263

    Article  PubMed  Google Scholar 

  5. Kim MJ, Kim S, Yu YS (2008) The risk for retinal detachment associated with hemorrhages pre and postlaser treatment in retinopathy of prematurity. Retina 28:1451–1457

    Article  PubMed  Google Scholar 

  6. Vinekar A, Trese MT, Capone A Jr, Photographic Screening for Retinopathy of Prematurity (PHOTO-ROP) Cooperative Group (2008) Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol 145:548–555

    Article  PubMed  Google Scholar 

  7. Sonmez K, Drenser KA, Capone A Jr, Trese MT (2008) Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 115:1065–1070

    Article  PubMed  Google Scholar 

  8. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N (2000) Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 156:1337–1344

    CAS  PubMed  Google Scholar 

  9. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495–511

    Article  PubMed  Google Scholar 

  10. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606

    Article  CAS  PubMed  Google Scholar 

  11. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278

    Article  PubMed  Google Scholar 

  12. Mintz-Hittner HA, Kuffel RR (2008) Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28:831–838

    Article  PubMed  Google Scholar 

  13. Quiroz-Mercado H, Martinez-Castellanos MA, Hermamdez-Rojas ML, Salazar-Teran N, Chan RV (2008) Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28:S19–S25

    Article  PubMed  Google Scholar 

  14. Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727–1730

    Article  CAS  PubMed  Google Scholar 

  15. Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, Johnson RA, Puliafito CA (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:S13–S18

    Article  PubMed  Google Scholar 

  16. Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K (2007) Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 55:75–76

    Article  PubMed  Google Scholar 

  17. Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, Fujikado T (2008) Efficacy of intravitreal injection of Bevacizumab for severe retinopathy of prematurity: A pilot study. Br J Ophthalmol 92:1450–1455

    Article  CAS  PubMed  Google Scholar 

  18. Micieli JA, Surkont M, Smith AF (2009) A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 148:536–543

    Article  CAS  PubMed  Google Scholar 

  19. Schwarz Q, Gu C, Fujisawa H, Sabelko K, Gertsenstein M, Nagy A, Taniguchi M, Kolodkin AL, Ginty DD, Shima DT, Ruhrberg C (2004) Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve. Genes Dev 18:2822–2834

    Article  CAS  PubMed  Google Scholar 

  20. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53–67

    Article  CAS  PubMed  Google Scholar 

  21. Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chévez-Barrios P (2008) Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 126:1161–1163

    Article  PubMed  Google Scholar 

  22. Mintz-Hittner HA, Best LM (2009) Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr 21:182–187

    Article  PubMed  Google Scholar 

  23. An International Committee for Classification of Retinopathy of Prematurity (2005) The International Classification of Retinopathy of Prematurity. Arch Ophthalmol 123:991–999

    Article  Google Scholar 

  24. Parvaresh MM, Modarres M, Falavarjani KG, Sadeghi K, Hammami P (2009) Transscleral diode laser retinal photocoagulation for the treatment of threshold retinopathy of prematurity. J AAPOS 13:535–538

    Article  PubMed  Google Scholar 

  25. Chen J, Smith LE (2007) Retinopathy of prematurity. Angiogenesis 10:133–140

    Article  PubMed  Google Scholar 

  26. Löfqvist C, Andersson E, Sigurdsson J, Engström E, Hård AL, Niklasson A, Smith LE, Hellström A (2006) Longitudinal postnatal weight and insulin-like growth factor 1 measurements in the prediction of retinopathy of prematurity. Arch Opthalmol 124:1711–1718

    Article  Google Scholar 

  27. Kychenthal A, Dorta P, Katz X (2006) Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 26:S11–S15

    Article  PubMed  Google Scholar 

  28. Coats DK, Miller AM, Hussein MA, McCreery KM, Holz E, Paysse EA (2005) Involution of retinopathy of prematurity after laser treatment: factors associated with development of retinal detachment. Am J Ophthalmol 140:214–222

    Article  PubMed  Google Scholar 

  29. Coats DK (2005) Retinopathy of prematurity involution, factors predisposing to retinal detachment, and expected utility of preemptive surgical intervention. Trans Am Ophthalmol Soc 103:281–312

    PubMed  Google Scholar 

  30. Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG (2007) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216

    Article  PubMed  Google Scholar 

  31. Honda S, Hirabayashi H, Tsukahara Y, Negi A (2008) Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 246:1061–1063

    Article  CAS  PubMed  Google Scholar 

  32. Avery RL (2009) Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern. J AAPOS 13:329–331

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eye research center, Iran University of Medical Sciences, Rassoul Akram hospital, Sattarkhan-Niayesh Street, Tehran, 14455-364, Iran

    Hossein Nazari, Mehdi Modarres, Mohammad Mehdi Parvaresh & Khalil Ghasemi Falavarjani

Authors
  1. Hossein Nazari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehdi Modarres
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Mehdi Parvaresh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Khalil Ghasemi Falavarjani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hossein Nazari.

Additional information

Financial Support

Eye research center, Iran University of Medical Sciences

Financial relationship exists with the organization that sponsored the research

Conflict of interest

No authors have any financial/conflicting interests in the products mentioned in the article

Authors have had full control of all primary data and they agree to allow Graefes Archive for Clinical and Experimental Ophthalmology to review their data upon request.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nazari, H., Modarres, M., Parvaresh, M.M. et al. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 248, 1713–1718 (2010). https://doi.org/10.1007/s00417-010-1430-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-010-1430-x

Keywords

Search

Navigation